CURRICULUM VITAE

Marco Ladetto MD,

Personal data

Date of birth: February 7, 1968
Place of birth: Torino, Italy, EU

Citizenship: Italian

Marital Status: Married; one female child aged 16 years

Mailing address: Marco Ladetto MD

Director Hematology Division

c/o divisione di Ematologia (III piano) Padiglione Fiandesio

AO SS Antonio e Biagio e C. Arrigo

Via Venezia n. 16 - 15100 Alessandria Italy EU

Contacts: tel +39 0131 206262 or + 39 0131 2061156

mail1 : marco.ladetto@ospedale.al.it mail2 : marco.ladetto@uniupo.it

Education

1992 Medical degree (with distinction), University of Torino, Italy, EU

1997 Postgraduate degree in Hematology (with distinction), University of

Torino, Italy, EU

Professional records

1990-1992	Internship, Division of Hematology, University of Torino, Italy EU
1993	Military Service as Medical Official in the Italian Military Police Force
1994-1997	Post-doctoral fellow, Division of Hematology, University of Torino, Italy, EU
1998-1999	Research fellow, Department of Adult Oncology, Dana Farber Cancer
	Institute, Harvard Medical School, Boston MA USA
1999-2013	Assistant Professor in Hematology, Division of Hematology, University
	of Torino, Italy, EU
2013-17	National Eligibility for Associate Professorship
2014-20	Head of Hematology Division at AO SS Antonio e Biagio e C. Arrigo,
	Alessandria, Italy, EU
2017-20	National Eligibility for Full Professorship
2020	Associate Professor in Haematology, Department or Translational
	Medicine, University of Eastern Piedmont

Teaching employments

2000-2013	Lecturer and tutor on "Hematology" in the Biotechnology course of the
	University of Torino, Italy EU.
2004-2013	Lecturer and tutor on "Hematology" in the Medicine course of the
	University of Torino Italy EU,.
2000-2017	Lecturer and tutor on "Hematology" in the Postgraduate school of the
	University of Torino Italy EU.
2016-2020	Lecturer and tutor on "Blood Disorders" in the Biology course of the
	University of Piemonte Orientale
2016-2020	Lecturer and tutor on "Haematology" at the Postgraduate Hematology
	school of the University of Piemonte Orientale
2015-2020	Lecturer on "Minimal residual disease" and Mantle Cell Lymphoma at
	the Lymphoma Master of the University of Udine

Clinical activity

- 1999 -2013 Attending physician at Divisione Universitaria di Ematologia (in-patient and out-patient care)
- 2014-20 Head of Hematology Division AO SS Antonio e Biagio e C. Arrigo, Alessandria, Italy EU (in-patient out-patient and stem cell Transplantation Unit)

-

Current and previous grant (last fifteen years) support

- International Myeloma Foundation, USA
- Regione Piemonte, Italy EU
- Associazione Italiana ricerca sul Cancro (AIRC), Italy, EU
- Ministero del Welfare, Salute e Politiche Sociali, Italy, EU
- MInistero dell'Università e della Ricerca (MIUR) (including "progetti di rilevante interessa Nazionale" (PRIN), Italy, EU
- · Roche Pharma, International, Switzerland
- Roche Pharma, Italy, EU
- Celgene Pharma USA
- Gilead Pharma, USA
- University of Munich
- Fondazione Italiana Linfomi

Editorial activity and activity with Scientific Societies

- 2000-2020 Reviewer for Blood, Journal of Clinical Oncology, Lancet Oncology, Leukemia, Haematologica, Annals of Medicine, and Hematological Oncology, Blood Reviews, etc
- 2013-2018 Section Editor for the "Hematological Malignancies-Lymphoma Section" of the "ESMO Clinical Guidelines"
- 2018-2020 Member of The Guidelines Committee of the European Society of Haematology
- 2016-2020 Member of the Executive Board of "Euro-MRD a branch of the European Society of Laboratory Hemato-Oncology"
- 2013-2017 Responsible of the "Biological Studies Committee" from Fondazione Italiana Linfomi (FIL)
- 2013-2020 Member of the Executive Board of Fondazione Italiana Linfomi
- 2009-2020 Member of the European Mantle Cell Lymphoma nework
- Memberr of the American Society of Haematology (ASH) European Society of Haematology (EHA) European Society of Clinical Oncology (ESMO) and Società Italiana di Ematologia (SIE)
- Nominated Faculty coordinator of the Education Program for Hematologic Malignancies of the European Society of Medical Oncology (ESMO) starting 1st January 2021

_

Clinical Research

PI of three clinical studies. National PI of one pan-european study Member of the Steering Committee of 12 Clinical studies

Local PI in > 20 studies

Member of DSMC in five study (Sponsor: LYSARC, France, EU, IQVIA East Asia, Singapore, Acerta Pharmaceuticals NJ, USA, Ulm University, Germany, Regeneron Pharmaceuticals NY, USA))

Scientific referent for Minimal Residual Disease evaluation in 10 studies

Scientific interests

- Diagnosis prognosis and treatment of lymphoma, myeloma and chronic lymphocytic leukemia
- Minimal residual disease assessment by qualitative and quantitative PCR
- Biological prognostic factors in non Hodgkin lymphoma, multiple myeloma and chronic lymphocytic leukemia
- Lymphomagenesis and lymphoma-related translocations

Scientific Production:

N of Peer-rewiew papers (source SCOPUS): 159

N peer review papers since 2010 (source SCOPUS): 100

N of Citations (source SCOPUS): 7246

N of Citations 2004-2019 (fonte SCOPUS): 5121

Total H-Index totale (fonte SCOPUS): 48

H-index 2005-2019 (fonte SCOPUS): 40

Total Impact factor*: 1348,81

Impact factor* first, second, second-last penultimo and last name: 678,33

Impact factor* first and last name (including shared autorships): 511,83

Speaker at > 200 National and International Meetrings including 11 "oral presentations" at the American Society of Hematology (ASH) Meeting

^{*}Calculated on 2019 Impact Factor parameters